Tesofensine Results: Week-by-Week Timeline

Months 1-2: The Weight-Loss Trajectory Becomes Visible

This is where the documented weight-loss curve becomes the dominant story.

What the trial documented:

• Across the full 24-week Phase 2 trial, Astrup et al. (2008) documented mean weight loss of 9.2% at 0.5 mg, 4.5% at 0.25 mg, and 10.6% at 1.0 mg, each combined with diet, versus 2.0% with diet plus placebo (Astrup et al., 2008).
• Earlier neurological trials in Parkinson's and Alzheimer's patients — run without any weight-loss program — had already documented dose-dependent weight loss as a consistent effect over 14 weeks, with the obese subgroup losing the most (Astrup et al., 2008, Obesity).

What community sources describe:

• Self-reported community timelines describe steady weekly weight loss through this window at the 0.5 mg amount, with the rate tied closely to diet adherence.
• Community reports cluster around the appetite suppression remaining strong through roughly weeks 4-6, after which some users describe it beginning to soften.
• Users in community sources commonly describe watching resting heart rate during this stretch, since the trial documented an increase of roughly 7 beats per minute at 0.5 mg (Astrup et al., 2008).

Realistic framing: the trial figures are mean values combined with a controlled diet, not a guaranteed personal outcome. Astrup et al. (2008) documented that the 0.5 mg dose roughly doubled the loss seen with anti-obesity drugs available at the time, but it did so in a structured trial setting, not as a standalone effect.

Months 3-6: Approaching and Extending the Trial Window

The published controlled data runs to 24 weeks (roughly six months), so this is the edge of what trials documented.

What the trial documented:

• The 0.5 mg arm reached 9.2% mean weight loss at the 24-week endpoint of the Phase 2 trial (Astrup et al., 2008).
• Astrup et al. (2008) noted the weight-loss curve had not clearly plateaued by week 24, which the authors described as suggesting further loss might occur with longer treatment — a hypothesis no published controlled trial has since confirmed (Astrup et al., 2008).
• The trial also documented preferential fat-mass loss with relative preservation of lean mass as a secondary finding over the 24 weeks (Astrup et al., 2008).

What community sources describe:

• Community protocols typically describe an 8-weeks-on, 4-weeks-off structure rather than continuous use, citing tolerance to the monoamine effects.
• Self-reported community timelines describe the off-cycle as a period where appetite returns toward baseline, with weight maintenance depending on diet.
• The most consistent community feedback is that results past the trial window are individual and undocumented in controlled data.

Realistic framing: beyond 24 weeks, there is no published controlled trial to anchor expectations. Everything past that point rests on self-reported community experience, which is not equivalent to trial evidence.

Factors That Affect Results

Several variables shaped response in the trial and in community reports.

Dose. Astrup et al. (2008) documented a clear dose-response curve: 4.5% at 0.25 mg, 9.2% at 0.5 mg, 10.6% at 1.0 mg over 24 weeks. The jump from 0.25 mg to 0.5 mg nearly doubled the documented loss, while 0.5 mg to 1.0 mg added far less with more adverse events (Astrup et al., 2008). This is why community sources cluster at 0.5 mg.

Diet. Every weight-loss figure in the Phase 2 trial was generated alongside a controlled diet (Astrup et al., 2008). Gilbert et al. (2012) documented that the appetite mechanism makes a deficit easier to sustain, but the deficit still has to exist (Gilbert et al., 2012).

Baseline weight. The neurological trials documented the largest weight loss in the obese subgroup, suggesting more baseline weight tracked with larger documented change (Astrup et al., 2008, Obesity).

Consistency and timing. Because the parent compound has a long half-life, steady-state effects build over weeks. Community sources commonly describe consistent morning dosing and reduced caffeine to manage stimulant overlap.

Tolerance. Community reports cluster around appetite suppression softening after several weeks, which is the stated rationale for the 8-on/4-off cycling community protocols describe.

When to Adjust

Reporting what trials and community sources have documented around adjustment — not instructions.

Signs the protocol is tracking the documented response: community reports cluster around early appetite suppression in weeks 1-4, followed by steady scale movement when a diet deficit is present, mirroring the trial's appetite-then-weight sequence documented by Gilbert et al. (2012) and Astrup et al. (2008).

Signs of the trial-documented adverse profile: Astrup et al. (2008) documented increased heart rate (~7 bpm at 0.5 mg), dry mouth, insomnia, nausea, and constipation. The trial reported discontinuation in subjects when cardiovascular or psychiatric effects became significant (Astrup et al., 2008).

What if a user sees nothing: in the Phase 2 trial, response varied and the compound was always paired with a controlled diet (Astrup et al., 2008). Self-reported community sources describe re-examining diet adherence, dose timing, and tolerance status before concluding a protocol is not working. None of that is medical advice; physician supervision with cardiovascular monitoring is the conservative path given the documented heart-rate effect.

Related Reading

• Tesofensine Dosing Guide — community protocols, cycling, timing, and half-life detail
• Tesofensine Benefits — five documented effects ranked by evidence strength
• Tesofensine Buying Guide — small-molecule sourcing and purity standards
• Tesofensine Clinical Trials — Phase 2 data, Tesomet updates, and FDA pathway
• Calculate Your Tesofensine Cycle Cost — estimate cost for a given protocol

References

For educational and research purposes only. This is not medical advice. Tesofensine is not FDA-approved for any indication.